Abraxis deal done, Celgene eyes cancer franchise

Celgene has wrapped up its $3 billion-plus buyout of Abraxis BioScience.
Now that Celgene has wrapped up its $3 billion-plus buyout of Abraxis BioScience, analysts are cheering. That wasn't necessarily the case in June, when the companies announced their deal--and investors responded by selling off their stock, sending the price plummeting to $48. But as Investor's Business Daily reports, Celgene shares are now trading at near $60, and observers think the combo will eventually transform the company into a "biopharmaceutical giant."
Celgene specializes in drugs for blood cancers, with its Revlimid drug leading the company's roster. Abraxis, on the other hand, sports a promising drug for solid tumors, Abraxane. Analysts think that Celgene can beef up Abraxane sales significantly, because it already fields a cancer-drug sales force. Up to $500 million from $315 million last year, one analyst predicts.
But even more importantly, Abraxane has the potential to be a "platform drug" used to treat several forms of cancer. Now approved for brea
Related News
-
News Strategies for managing an outsourcing partner
Robust oversight linked to increased efficiency and better communication with outsourcing partners. -
News Updated: CPHI North America 2022 Blog
Follow along for live updates from CPHI North America, taking place in Philadelphia, PA from May 17-19. -
News Greater standardisation needed for effective ESG reporting - Expert panel
Increased transparency and standardisation in ESG reporting frameworks is emerging as a key requirement for investors. -
News MedPharm: Increased investment driving developments in topical drugs market
We caught up with MedPharm at CPHI North America to discuss opportunities in the topical and transdermal products space. -
News Pharmapack Awards 2022: Winners Revealed
The jury assessed a wide range of industry-changing innovations in packaging and drug delivery, ultimately selecting seven winners. -
News What it means to be 'At the heart of Pharma'
Informa Markets colleagues explain the motivations behind CPHI’s rebrand. -
News CPhI Podcast Series: Leveraging data science for sustainable autoinjector development
Environmental impact is an area of increasing focus for the pharma and biopharma industries, with companies like Merck, Pfizer and GlaxoSmithKline setting ambitious targets for carbon neutrality and laying plans for waste reduction. -
News Thermo Fisher and Charles River join consortium using robotics to produce cell therapies at scale
The Consortium aims to increase the scale of cell therapy manufacturing to a level impossible with current manual processes.
Position your company at the heart of the global Pharma industry with a CPhI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPhI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance